NEW YORK (GenomeWeb News) – Sigma-Aldrich today reported that its third-quarter revenues dipped 1.3 percent year over year, with growth in its Research Biotech and fine chemicals (SAFC) businesses being offset by declines in its other units.

The chemicals and lab products firm generated total revenues of $533.8 million for the three-month period ended Sept. 30, compared to revenues of $540.6 million for the third quarter of 2008. Excluding the negative impact of currency translation, Sigma-Aldrich's sales grew around 2 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.